View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 17, 2015

Allergan to buy Kythera Biopharmaceuticals for $2.1bn

Irish company Allergan has signed an agreement to acquire US-based Kythera Biopharmaceuticals for around $2.1bn.

Irish company Allergan has signed an agreement to acquire US-based Kythera Biopharmaceuticals for around $2.1bn.

Free Report
img

How is the Biopharmaceutical industry evolving?

2021 was a year of continued innovation and change in the Biopharmaceutical industry. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape. GlobalData’s expansive report examines the business environment and trends that shape the Biopharmaceutical industry. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects. Access the report to:
  • Benchmark the impact of major themes on the Biopharmaceutical industry.
  • Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents.
  • Evaluate the effects of COVID-19 on the sector.
Download the full report to understand what to expect and how to align your strategies for success.
by GlobalData
Enter your details here to receive your free Report.

Under the deal, Allergan will pay $75 per Kythera share, including 80% payment in cash and 20% in new shares to Kythera shareholders in Allergen.

Kythera is involved in the discovery, development and commercialisation of new prescription products for the aesthetic medicine market.

Allergan president and CEO Brent Saunders said: "The acquisition of Kythera is a strategic investment that strengthens our leading global position in aesthetics and continues to position us for long-term growth."

"The acquisition of Kythera is a strategic investment that strengthens our leading global position in aesthetics and continues to position us for long-term growth."

The acquisition will expand Allergan’s global facial aesthetics portfolio with the addition of Kythera’s lead product Kybella (deoxycholic acid) injection.

Kybella is claimed to be the first and only approved non-surgical treatment for contouring moderate to severe submental fullness, otherwise known as a double chin.

In April, Kybella received approval from the US Food and Drug Administration (FDA) and is also being developed to be introduced to the international markets.

The company submitted applications for Kybella for regulatory approval in Switzerland, Canada, and Australia and plans make further submissions in several other countries.

The deal will also allow Allergen to acquire Kythera’s development product setipiprant (KYTH-105), a new compound to prevent male pattern baldness, as well as additional early stage development candidates.

Kythera CEO and president Keith Leonard said: "Allergan’s world-class medical aesthetics, global footprint, history and commitment to developing leading aesthetic products makes them ideally suited to realise the maximum commercial potential of Kybella."

Subject to approval by the shareholders of Kythera and certain other customary conditions, the deal is expected to be completed in the third quarter of this year.

Related Companies

Free Report
img

How is the Biopharmaceutical industry evolving?

2021 was a year of continued innovation and change in the Biopharmaceutical industry. As the COVID-19 pandemic continues to take its toll on businesses worldwide, it’s time to look for new ways to create value, prepare for the future, and remain competitive in the ever-changing landscape. GlobalData’s expansive report examines the business environment and trends that shape the Biopharmaceutical industry. We highlight the most impactful emerging technologies, as well as the industry, regulatory, and macroeconomic factors that influence growth prospects. Access the report to:
  • Benchmark the impact of major themes on the Biopharmaceutical industry.
  • Gain a deeper "on the ground" perspective through exclusive opinions and analysis from industry respondents.
  • Evaluate the effects of COVID-19 on the sector.
Download the full report to understand what to expect and how to align your strategies for success.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology